Silverleafe Capital Partners’s XBiotech XBIT Stock Holding History

Silverleafe Capital Partners’s Portfolio XBIT Stock Details XBIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-24,000	Closed	-$448K	–	77
2019 Q4	$448K	Buy	+24,000	New	+$309K	0.25%	50

Other funds holding XBIT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Silverleafe Capital Partners's XBIT Position: Q1 2020 in Review

Silverleafe Capital Partners sold out of XBiotech (XBIT) in Q1 2020, closing a stake of 24,000 shares — an estimated $448K sold.

Silverleafe Capital Partners first reported a position in XBIT in Q4 2019 and held it in 1 quarter. The position peaked at $448K in Q4 2019. 60 funds tracked by Wall St. Rank hold XBIT as of Q1 2020.

Silverleafe Capital Partners reported no remaining XBiotech position as of Q1 2020 after selling out during the quarter.
Silverleafe Capital Partners sold 24,000 XBiotech shares in Q1 2020, an estimated $448K.
Silverleafe Capital Partners first reported a position in XBiotech in Q4 2019 and held it in 1 quarter.
Silverleafe Capital Partners's XBiotech position peaked at $448K in Q4 2019.
60 funds tracked by Wall St. Rank held XBiotech as of Q1 2020.

Based on Silverleafe Capital Partners's 13F filing for Q1 2020, filed 7 Apr 2020.